A Comparative Study for Iohexol and Ioversol Effects on Renal Function in Patients with Coronary Artery Intervention Treatment

Songlin Shen; Binxia Zhu; Renfeng Zhang

doi:doi:10.11648/j.sd.20241206.11

Research Article |

| Peer-Reviewed

A Comparative Study for Iohexol and Ioversol Effects on Renal Function in Patients with Coronary Artery Intervention Treatment

Songlin Shen

, Binxia Zhu

, Renfeng Zhang^*

Published in Science Discovery (Volume 12, Issue 6)

Received: 21 October 2024 Accepted: 27 November 2024 Published: 7 December 2024

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Objective: To compare the effects of iohexol and ioversol on the incidence of contrast induced nephropathy (CIN) and renal function in patients who received percutaneous coronary intervention (PCI); to investigate the related risk factors of CIN in patients after PCI; to evaluate the preventative effect of different dose of atorvastatin on the incidence of CIN in the patients after PCI. Methods: 140 patients who received PCI were chosen as research subjects in the Third People's Hospital of Mianyang from June 2013 to March 2015, which were randomly divided into iohexol group and ioversol group (74 cases for iohexol group, 66 cases for ioversol group). It was recorded that the patients’ general condition, blood routine test, urine examination, renal function, etc before and after PCI. And it was observed after PCI that the dosage of contrast material, the numbers of damaged coronary artery and implanting stent, the exposure time of contrast material, etc. Results: The incidences of CIN for iohexol and ioversol were not significantly different (P > 0.05). The differences between the two groups in the Serum creatinine (Scr), blood urea nitrogen (BUN), glomerular filtration rate (GFR), urine β2- microglobulin (β2-MG), and cystatin C (Cys C) before and after PCI were not obvious (P > 0.05) ; the changes of Scr, β₂-MG, CysC, GFR of the patients before and after PCI in the two groups were significant (P<0.05), but the change of BUN was not significant (P > 0.05).Through multiple regression analysis, it was found that type 2 diabetes (OR = 9.560, P=0.001), two coronary artery implanting stents (OR = 6.252, P=0.044), three and above coronary artery implanting stents (OR=12.499, P=0.009) were independent risk factors of CIN. It was not significantly different that the effects of 20mg atorvastatin and 40mg atorvastatin on the incidence of CIN, Scr and GFR (P>0.05). Conclusion: There are no significant differences in the incidence of CIN and renal function for PCI patients with ioversol or iohexol. Moreover, diabetes and two or more coronary artery implanting stents are independent risk factors for CIN in PCI patients. It doesn’t show any benefits for PCI patients to take the large dose of atorvastatin to prevent CIN before operation.

Published in	Science Discovery (Volume 12, Issue 6)
DOI	10.11648/j.sd.20241206.11
Page(s)	145-155
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

Iohexol, Ioversol, Contrast Induced Nephropathy, Renal Function, Cystatin C, Urine β2-Microglobulin, Percutaneous Coronary Intervention

References

[1]	Nash K, Hafeez A, Hou S. HosPital-acquiredrenal insuficieney [J]. Am J Kidney Dis, 2002; 39: 930-936.
[2]	Briguori C, Airoldi F, Morici N, et a1. New pharmacological protocols to prevent or reduce contrast mediane phropathy [J]. Minerva Cardioangiol, 2005; 53(1): 49-58.
[3]	Lun, Zhubin et al. “The global incidence and mortality of contrast-associated acute kidney injury following coronary angiography: a meta-analysis of 1.2 million patients.” Journal of nephrology vol. 34, 5 (2021): 1479-1489. https://doi.org/10.1007/s40620-021-01021-1
[4]	KDIGO AKI Work Group. KDIGO clinical practice guideline for acute kidney injury [J]. Kidney International, 2012; 2: 1-138.
[5]	Klause N, Arendt T, Lins M, et al. Hypoxic renal tissue damage by endothelin-mediated arterial vasoconstriction during radioangiography in man [J]. Adv Exp Med Biol, 1998; 454: 225-234.
[6]	Pannu N, Manns B, Lee H, et al. Systematic review of the impact of N—acetylcysteine on contrast nephropathy [J]. Kidney Int, 2004; 65(4): 1366-1374.
[7]	Zhao Y, Tao Z, Xu Z, et al. Toxic effects of a high dose of non-ionic iodinated contrast media on renal glomerular and aortic endothelial cells in aged rats in vivo [J]. Toxicol Lett, 2011; 202: 253-260.
[8]	Marenzi G, Lauri G, Assanelli E, et al. Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction [J]. J Am Coll Cardiol, 2004; 44 9): 1780-1785.
[9]	Schilp J, de Blok C, Langelaan M, et al. Guideline adherence for identification and hydration of high-risk hospital patients for contrastinduced nephropathy [J]. BMC Nephrology, 2014; 15: 2.
[10]	Sany D, Refaat H, Elshahawy Y, et al. Frequency and riskfactors of contrast-induced nephropathy after cardiac catheterization in type Ⅱ diabetic patients: a study among Egyptian patients [J]. Ren Fail, 2014; 36(2): 191-197.
[11]	姚英. 2018年欧洲泌尿生殖放射学会造影后急性肾损伤防治指南的解读 [J]. 中国血液净化, 2019, 18(06): 435-438.
[12]	Barrett BJ, Carlisle EJ. Metaanalysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media [J]. Radiology, 1993; 188(1): 171-178.
[13]	Aspelin P, Aubry P, Fransson S-G, et al．Nephrotoxic effects in high-risk patients undergoing angiography [J]. New England Journal of Medicine, 2003; 348(6): 491-499.
[14]	From A, AlBadarin F, McDonald F, et al. Iodixanolversu slow- osmolar contrast media for prevention of contrast induced nephropa- thy meta analysis of randomized, controlled trials [J]. Circulation, 2010; 3: 351-358.
[15]	hen Y, Hu S, Liu Y, et al. Renal tolerability of iopromide and iodixanol in 562 renally impaired patients undergoing cardiac catheterisation: the DIRECT study. EuroIntervention. 2012; 8(7): 830-838. https://doi.org/10.4244/EIJV8I7A126
[16]	Seong JM, Choi NK, Lee J, et al. Comparison of the safety of seven iodinated contrast media [J]. J Korean Med, 2013; 28(12): 1703-1710.
[17]	Stacul F, van der Molen AJ, Reimer P, et al. Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines. Contrast Media Safety Committee of European Society of Urogenital Radiology (ESUR) [J]. Eur Radiol, 2011; 21(12): 2527-2527.
[18]	Hou SH, Bushinsky DA, Wish JB, et a1. Hospital-acquired renal insufficiency: a prospective study [J]. Am J Med, 1983; 74(2): 243-248.
[19]	Giancarlo M, Gianfranco L, Emilio A, et a1. Contrast-Induced Nephropathy in Patients Undergoing Primary Angioplasty for Acute Myocardial Infarction [J]. J Am Coll Cardiol,2004;44:1780-1785.
[20]	Farhan S, Vogel B, Tentzeris I, et al. Contrast induced acute kidney injury in acute coronary syndrome patients: A single centre experience [J]. Eur Heart J Acute Cardiovasc Care,2015;4(1): 99-102.
[21]	Abe M, Morimoto T, Akao M, et al. Relation of contrast-induced nephropathy to long-term mortality after percutaneous coronary intervention [J]. Am J Cardiol, 2014; 114(3): 362-368.
[22]	Wright RS, Reeder GS, Herzog CA, et al. Acute Myocardial Infarction and Renal Dysfunction: A High-Risk Combination [J]. Ann Intern Med, 2002; 137: 563-570.
[23]	Barrett BJ, Carlisle EJ. Meta analysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media [J]. Radiology, 1993; 188(1): 171-178.
[24]	McCullough PA, Bertrand ME, Brinker JA, et al. A meta-analysis of the renal safety of isosmolar iodixanol compared with low-osmolar contrast media [J]. Journal of the American College of Cardiology, 2006; 48(4): 692-699.
[25]	Heinrich MC, Häberle L, Müller V, et al. Nephrotoxicity of iso- osmolar iodixanol compared with nonionic low-osmolar contrast media: meta-analysis of randomized controlled trials [J]. Radiology, 2009; 250(1): 68-86.
[26]	Solomon R. The role of osmolality in the incidence of contrast induced nephropathy: a systematic review of angiographic contrast media in high risk patients[J]. Kidney International, 2005; 68(5): 2256-2263.
[27]	Beaufils H, Idee JM, Berthommier C, et al. Iobitridol, a new nonionic low-osmolality contrast agent, and iohexol. Impact on renal Histology in the rat [J]. Invest Radiol, 1995; 30: 33-39.
[28]	Tervahartiala P, Kivisaari L, Kivisaari R, et al. Structural Changes in the renal proximal tubular cells induced by iodinated contrast media [J]. Nephron, 1997; 76: 96-102.
[29]	Guitterez NV, Diaz A, Timmis GC, et al. Determinants of serum creatinine trajectory in acute contrast nePhroPathy [J]. J Interv Cardiol, 2002; 15: 349-354.
[30]	Ebru AE, Kilic A, Korkmaz FS, et al. Is cystatin-C superior to creatinine in the early diagnosis of contrast-induced nephropathy?: a potential new biomarker for an old complication [J]. J Postgrad Med, 2014; 60(2): 135-140.
[31]	Barrett BJ, Parfrey PS. Preventing nephropathy induced by contrast medium [J]. N Engl J Med, 2006; 354: 379-386.
[32]	Bachorzewska-Gajewska H, Malyszko J, Sitniewska E, et al. Neutrophil-gelatinase-associated lipocalin and renal function after percutaneous coronary interventions [J]. Am J Nephrol,2006;26(3): 287-292.
[33]	Ling W, Zhaohui N, Ben H, et al. Urinary IL-18 and NGAL as early predictive biomarkers in contrast-induced nephropathy after coronary angiography [J]. Nephron Clin Pract, 2008; 108(3): c176-c181.
[34]	马玉良, 王伟民, 刘健, 等. 超敏C反应蛋白与对比剂肾病关系研究 [J]. 中国循环杂志, 2009; 24(6): 418-420.
[35]	Schilp J, de Blok C, Langelaan M, et al. Guideline adherence for identification and hydration of high-risk hospital patients for contrastinduced nephropathy [J]. BMC Nephrology, 2014; 15:2.
[36]	Sany D, Refaat H, Elshahawy Y, et al. Frequency and riskfactors of contrast-induced nephropathy after cardiac catheterization in type Ⅱ diabetic patients: a study among Egyptian patients [J]. Ren Fail, 2014; 36(2): 191-197.
[37]	KDIGO AKI Work Group. KDIGO clinical practice guideline for acute kidney injury [J]. Kidney International, 2012; 2: 1-138.
[38]	Marenzi G, Lauri G, Assanelli E, et al. Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction [J]. J Am Coll Cardio, 2004; 44(9): 1780-1785.
[39]	Chong E, Poh KK, Liang S, Tan HC. Risk factors and clinical Outcomes for contrast-induced nephropathy after pereutaneous coronary Intervention in Patients with normal serum creatinine [J]. Ann Acad Med Singapore, 2010; 39: 374-380.
[40]	Marenzi G, Assanelli E, Campodonico J, et al.contrast volume dering primary pecutaneous coronary intervention and subsequent contrast-induced nephropathy and mortality [J]. Ann Intern Med, 2009; 150(3): 170-177.
[41]	Chong E, Poh KK, Liang S, et al. Risk Factors and Clinical Outcomes for Contrast-induced Nephropathy After Percutaneous Coronary Intervention in Patients with Normal Serum Creatinine [J]. Ann Acad Med Singapore, 2010; 39: 374 -380.
[42]	Sany D, Refaat H, Elshahawy Y, et al. Frequency and riskfactors of contrast-induced nephropathy after cardiac catheterization in type Ⅱ diabetic patients: a study among Egyptian patients [J]. Ren Fail, 2014; 36(2): 191-197.
[43]	冠心病介入诊疗对比剂应用专家共识组.冠心病介入诊疗对比剂应用专家共识 [J]. 中国心血管病研究, 2010; 8(12): 881-889.
[44]	杨琛, 时永辉, 訾瑞峰, 等. PCI引起冠心病患者血清ox - Lp(a)和 2- GPI-ox-Lp(a)水平升高 [J]. 标记免疫分析与临床, 2014; 21(3): 221-224.
[45]	Kunadian V, Zaman A, Spyridopoulos I, et al. Sodium bicarbonate for the prevention of contrast induced nephropathy: a meta-analysis of published clinical trials [J]. Eur J Radiol, 2011; 79(1): 48-55.
[46]	Klima T, Christ A, Marana I, et al. Sodium chloride vs sodium bicarbonate for the prevention of contrast mediuminduced nephropathy: a randomized Controlled trial [J]. European Heart Journal, 2012; 33(16): 2071-2079.
[47]	Samuel N, Heyman, MD, Seymour Rosen, MD, et al. Reactive Oxygen Species and the Pathogenesis of Radiocontrast-Induced Nephropathy [J]. Invest Radiol, 2010; 45: 188-195.
[48]	Patti G, Nusca A, Chello M, et al. Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention [J]. Am J Cardiol, 2008; 101(3): 279-285.
[49]	Melfi R, Nusca A, Patti G, et al. Statins and their role in pre-percutaneous coronary intervention [J]. Curr Cardiol Rep, 2010; 12(4): 295-301.
[50]	Eisen A, Leshem-Lev D, Yavin H, et al. Effect of High Dose Statin Pretreatment on Endothelial Progenitor Cells After Percutaneous Coronary Intervention (HIPOCRATES Study) [J]. Cardiovasc Drugs Ther, 2015; 25: 1-7.
[51]	Perticone F, Maio R, Perticone M, et al. Endothelial dysfunction and subsequent decline in glomerular filtration rate in hypertensive patients [J]. Circulation, 2010; 122: 379-384.
[52]	Werner N, Kosiol S, Schiegl T, et al. Circulating endothelial progenitor cells and cardiovascular outcomes [J]. N Engl J Med, 2005; 353: 999-1007.
[53]	Chiang C-H, Huang P-H, Chiu C-C, et al. Reduction of Circulating Endothelial Progenitor Cell Level Is Associated with Contrast In- duced Nephropathy in Patients Undergoing Percutaneous Coronary and Peripheral Interventions [J]. PLoS ONE, 2014; 9(3): e89942.
[54]	曹世平, 王鹏, 崔凯, 等. 阿托伐他汀通过抑制氧化应激预防对比剂肾病 [J]. 南方医科大学学报, 2012; 32(11): 1600-1602.
[55]	Han Y, Zhu G, Han L, et al. Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease [J]. J Am Coll Cardiol, 2014; 63(1): 62-70.
[56]	Leoncini M, Toso A, Maioli M, et al. Early high-dose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome: Results from the PRATO-ACS Study (Protective Effect of Rosuvastatin and Antiplatelet Therapy On contrast-induced acute kidney injury and myocardial damage in patients with Acute Coronary Syndrome) [J]. J Am Coll Cardiol, 2014; 63(1): 71-79.
[57]	Kenaan M, Seth M, Aronow HD, et al. Preprocedural statin use in patients undergoing percutaneous coronary intervention [J]. Am Heart J, 2014; 168(1): 110-116.
[58]	Abaci O, Arat Ozkan A, Kocas C, et al. Impact of rosuvastatin on contrast-induced acute kidney injury in patients at high risk for nephropathy undergoing elective angiography [J]. Am J Cardiol, 2015; 115(7): 867-871.

Cite This Article

Plain Text BibTeX RIS

APA Style

Shen, S., Zhu, B., Zhang, R. (2024). A Comparative Study for Iohexol and Ioversol Effects on Renal Function in Patients with Coronary Artery Intervention Treatment. Science Discovery, 12(6), 145-155. https://doi.org/10.11648/j.sd.20241206.11

Copy | Download

ACS Style

Shen, S.; Zhu, B.; Zhang, R. A Comparative Study for Iohexol and Ioversol Effects on Renal Function in Patients with Coronary Artery Intervention Treatment. Sci. Discov. 2024, 12(6), 145-155. doi: 10.11648/j.sd.20241206.11

Copy | Download

AMA Style

Shen S, Zhu B, Zhang R. A Comparative Study for Iohexol and Ioversol Effects on Renal Function in Patients with Coronary Artery Intervention Treatment. Sci Discov. 2024;12(6):145-155. doi: 10.11648/j.sd.20241206.11

Copy | Download

@article{10.11648/j.sd.20241206.11,
  author = {Songlin Shen and Binxia Zhu and Renfeng Zhang},
  title = {A Comparative Study for Iohexol and Ioversol Effects on Renal Function in Patients with Coronary Artery Intervention Treatment
},
  journal = {Science Discovery},
  volume = {12},
  number = {6},
  pages = {145-155},
  doi = {10.11648/j.sd.20241206.11},
  url = {https://doi.org/10.11648/j.sd.20241206.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.sd.20241206.11},
  abstract = {Objective: To compare the effects of iohexol and ioversol on the incidence of contrast induced nephropathy (CIN) and renal function in patients who received percutaneous coronary intervention (PCI); to investigate the related risk factors of CIN in patients after PCI; to evaluate the preventative effect of different dose of atorvastatin on the incidence of CIN in the patients after PCI. Methods: 140 patients who received PCI were chosen as research subjects in the Third People's Hospital of Mianyang from June 2013 to March 2015, which were randomly divided into iohexol group and ioversol group (74 cases for iohexol group, 66 cases for ioversol group). It was recorded that the patients’ general condition, blood routine test, urine examination, renal function, etc before and after PCI. And it was observed after PCI that the dosage of contrast material, the numbers of damaged coronary artery and implanting stent, the exposure time of contrast material, etc. Results: The incidences of CIN for iohexol and ioversol were not significantly different (P > 0.05). The differences between the two groups in the Serum creatinine (Scr), blood urea nitrogen (BUN), glomerular filtration rate (GFR), urine β2- microglobulin (β2-MG), and cystatin C (Cys C) before and after PCI were not obvious (P > 0.05) ; the changes of Scr, β2-MG, CysC, GFR of the patients before and after PCI in the two groups were significant (PP > 0.05).Through multiple regression analysis, it was found that type 2 diabetes (OR = 9.560, P=0.001), two coronary artery implanting stents (OR = 6.252, P=0.044), three and above coronary artery implanting stents (OR=12.499, P=0.009) were independent risk factors of CIN. It was not significantly different that the effects of 20mg atorvastatin and 40mg atorvastatin on the incidence of CIN, Scr and GFR (P>0.05). Conclusion: There are no significant differences in the incidence of CIN and renal function for PCI patients with ioversol or iohexol. Moreover, diabetes and two or more coronary artery implanting stents are independent risk factors for CIN in PCI patients. It doesn’t show any benefits for PCI patients to take the large dose of atorvastatin to prevent CIN before operation.
},
 year = {2024}
}

Copy | Download

TY  - JOUR
T1  - A Comparative Study for Iohexol and Ioversol Effects on Renal Function in Patients with Coronary Artery Intervention Treatment

AU  - Songlin Shen
AU  - Binxia Zhu
AU  - Renfeng Zhang
Y1  - 2024/12/07
PY  - 2024
N1  - https://doi.org/10.11648/j.sd.20241206.11
DO  - 10.11648/j.sd.20241206.11
T2  - Science Discovery
JF  - Science Discovery
JO  - Science Discovery
SP  - 145
EP  - 155
PB  - Science Publishing Group
SN  - 2331-0650
UR  - https://doi.org/10.11648/j.sd.20241206.11
AB  - Objective: To compare the effects of iohexol and ioversol on the incidence of contrast induced nephropathy (CIN) and renal function in patients who received percutaneous coronary intervention (PCI); to investigate the related risk factors of CIN in patients after PCI; to evaluate the preventative effect of different dose of atorvastatin on the incidence of CIN in the patients after PCI. Methods: 140 patients who received PCI were chosen as research subjects in the Third People's Hospital of Mianyang from June 2013 to March 2015, which were randomly divided into iohexol group and ioversol group (74 cases for iohexol group, 66 cases for ioversol group). It was recorded that the patients’ general condition, blood routine test, urine examination, renal function, etc before and after PCI. And it was observed after PCI that the dosage of contrast material, the numbers of damaged coronary artery and implanting stent, the exposure time of contrast material, etc. Results: The incidences of CIN for iohexol and ioversol were not significantly different (P > 0.05). The differences between the two groups in the Serum creatinine (Scr), blood urea nitrogen (BUN), glomerular filtration rate (GFR), urine β2- microglobulin (β2-MG), and cystatin C (Cys C) before and after PCI were not obvious (P > 0.05) ; the changes of Scr, β2-MG, CysC, GFR of the patients before and after PCI in the two groups were significant (PP > 0.05).Through multiple regression analysis, it was found that type 2 diabetes (OR = 9.560, P=0.001), two coronary artery implanting stents (OR = 6.252, P=0.044), three and above coronary artery implanting stents (OR=12.499, P=0.009) were independent risk factors of CIN. It was not significantly different that the effects of 20mg atorvastatin and 40mg atorvastatin on the incidence of CIN, Scr and GFR (P>0.05). Conclusion: There are no significant differences in the incidence of CIN and renal function for PCI patients with ioversol or iohexol. Moreover, diabetes and two or more coronary artery implanting stents are independent risk factors for CIN in PCI patients. It doesn’t show any benefits for PCI patients to take the large dose of atorvastatin to prevent CIN before operation.

VL  - 12
IS  - 6
ER  -

Copy | Download

Author Information

Songlin Shen

Department of Cardiology, The Third Hospital of Mianyang, Sichuan Mental Health Center, Mianyang, China

Contact Email

http://orcid.org/0009-0000-8255-5189
Binxia Zhu

Department of Cardiology, The Affiliated Hospital of Southwest Medical University, Luzhou, China

Contact Email

http://orcid.org/0009-0001-4880-7212
Renfeng Zhang

Department of Cardiology, Mianyang 404 Hospital, Mianyang, China

Contact Email

http://orcid.org/0000-0002-7435-1159

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Shen, S., Zhu, B., Zhang, R. (2024). A Comparative Study for Iohexol and Ioversol Effects on Renal Function in Patients with Coronary Artery Intervention Treatment. Science Discovery, 12(6), 145-155. https://doi.org/10.11648/j.sd.20241206.11

Copy | Download

ACS Style

Shen, S.; Zhu, B.; Zhang, R. A Comparative Study for Iohexol and Ioversol Effects on Renal Function in Patients with Coronary Artery Intervention Treatment. Sci. Discov. 2024, 12(6), 145-155. doi: 10.11648/j.sd.20241206.11

Copy | Download

AMA Style

Shen S, Zhu B, Zhang R. A Comparative Study for Iohexol and Ioversol Effects on Renal Function in Patients with Coronary Artery Intervention Treatment. Sci Discov. 2024;12(6):145-155. doi: 10.11648/j.sd.20241206.11

Copy | Download

@article{10.11648/j.sd.20241206.11,
  author = {Songlin Shen and Binxia Zhu and Renfeng Zhang},
  title = {A Comparative Study for Iohexol and Ioversol Effects on Renal Function in Patients with Coronary Artery Intervention Treatment
},
  journal = {Science Discovery},
  volume = {12},
  number = {6},
  pages = {145-155},
  doi = {10.11648/j.sd.20241206.11},
  url = {https://doi.org/10.11648/j.sd.20241206.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.sd.20241206.11},
  abstract = {Objective: To compare the effects of iohexol and ioversol on the incidence of contrast induced nephropathy (CIN) and renal function in patients who received percutaneous coronary intervention (PCI); to investigate the related risk factors of CIN in patients after PCI; to evaluate the preventative effect of different dose of atorvastatin on the incidence of CIN in the patients after PCI. Methods: 140 patients who received PCI were chosen as research subjects in the Third People's Hospital of Mianyang from June 2013 to March 2015, which were randomly divided into iohexol group and ioversol group (74 cases for iohexol group, 66 cases for ioversol group). It was recorded that the patients’ general condition, blood routine test, urine examination, renal function, etc before and after PCI. And it was observed after PCI that the dosage of contrast material, the numbers of damaged coronary artery and implanting stent, the exposure time of contrast material, etc. Results: The incidences of CIN for iohexol and ioversol were not significantly different (P > 0.05). The differences between the two groups in the Serum creatinine (Scr), blood urea nitrogen (BUN), glomerular filtration rate (GFR), urine β2- microglobulin (β2-MG), and cystatin C (Cys C) before and after PCI were not obvious (P > 0.05) ; the changes of Scr, β2-MG, CysC, GFR of the patients before and after PCI in the two groups were significant (PP > 0.05).Through multiple regression analysis, it was found that type 2 diabetes (OR = 9.560, P=0.001), two coronary artery implanting stents (OR = 6.252, P=0.044), three and above coronary artery implanting stents (OR=12.499, P=0.009) were independent risk factors of CIN. It was not significantly different that the effects of 20mg atorvastatin and 40mg atorvastatin on the incidence of CIN, Scr and GFR (P>0.05). Conclusion: There are no significant differences in the incidence of CIN and renal function for PCI patients with ioversol or iohexol. Moreover, diabetes and two or more coronary artery implanting stents are independent risk factors for CIN in PCI patients. It doesn’t show any benefits for PCI patients to take the large dose of atorvastatin to prevent CIN before operation.
},
 year = {2024}
}

Copy | Download

TY  - JOUR
T1  - A Comparative Study for Iohexol and Ioversol Effects on Renal Function in Patients with Coronary Artery Intervention Treatment

AU  - Songlin Shen
AU  - Binxia Zhu
AU  - Renfeng Zhang
Y1  - 2024/12/07
PY  - 2024
N1  - https://doi.org/10.11648/j.sd.20241206.11
DO  - 10.11648/j.sd.20241206.11
T2  - Science Discovery
JF  - Science Discovery
JO  - Science Discovery
SP  - 145
EP  - 155
PB  - Science Publishing Group
SN  - 2331-0650
UR  - https://doi.org/10.11648/j.sd.20241206.11
AB  - Objective: To compare the effects of iohexol and ioversol on the incidence of contrast induced nephropathy (CIN) and renal function in patients who received percutaneous coronary intervention (PCI); to investigate the related risk factors of CIN in patients after PCI; to evaluate the preventative effect of different dose of atorvastatin on the incidence of CIN in the patients after PCI. Methods: 140 patients who received PCI were chosen as research subjects in the Third People's Hospital of Mianyang from June 2013 to March 2015, which were randomly divided into iohexol group and ioversol group (74 cases for iohexol group, 66 cases for ioversol group). It was recorded that the patients’ general condition, blood routine test, urine examination, renal function, etc before and after PCI. And it was observed after PCI that the dosage of contrast material, the numbers of damaged coronary artery and implanting stent, the exposure time of contrast material, etc. Results: The incidences of CIN for iohexol and ioversol were not significantly different (P > 0.05). The differences between the two groups in the Serum creatinine (Scr), blood urea nitrogen (BUN), glomerular filtration rate (GFR), urine β2- microglobulin (β2-MG), and cystatin C (Cys C) before and after PCI were not obvious (P > 0.05) ; the changes of Scr, β2-MG, CysC, GFR of the patients before and after PCI in the two groups were significant (PP > 0.05).Through multiple regression analysis, it was found that type 2 diabetes (OR = 9.560, P=0.001), two coronary artery implanting stents (OR = 6.252, P=0.044), three and above coronary artery implanting stents (OR=12.499, P=0.009) were independent risk factors of CIN. It was not significantly different that the effects of 20mg atorvastatin and 40mg atorvastatin on the incidence of CIN, Scr and GFR (P>0.05). Conclusion: There are no significant differences in the incidence of CIN and renal function for PCI patients with ioversol or iohexol. Moreover, diabetes and two or more coronary artery implanting stents are independent risk factors for CIN in PCI patients. It doesn’t show any benefits for PCI patients to take the large dose of atorvastatin to prevent CIN before operation.

VL  - 12
IS  - 6
ER  -

Copy | Download